Cronos Group (CRON) P/S Ratio
Cronos Group (CRON) has a price-to-sales ratio of 6.63x, placing it in the Premium range for cannabis stocks. The company has a market cap of $939.0M and TTM revenue of $146.6M.
P/S Ratio (TTM)
6.63x
EV/Revenue
N/A
Market Cap
$939.0M
Revenue Growth
—
Valuation Breakdown
| Metric | Value |
|---|---|
| Stock Price | $2.56 |
| Market Capitalization | $939.0M |
| TTM Revenue | $146.6M |
| Price-to-Sales (TTM) | 6.63x |
| EV/Revenue | N/A |
| Revenue Growth (YoY) | — |
| Gross Margin | 42.8% |
| Sector | LP |
| Exchange | NASDAQ |
| Valuation Range | Premium |
Frequently Asked Questions
What is CRON's current price-to-sales ratio?+
The price-to-sales (P/S) ratio divides Cronos Group's market capitalization by its trailing twelve months of revenue. Since many cannabis companies are not yet profitable, P/S is one of the most widely used valuation metrics in the sector. A lower ratio may suggest the stock is undervalued relative to revenue.
How does CRON's P/S compare to other cannabis stocks?+
P/S ratios in cannabis typically range from 0.5x to 5x depending on growth rate, profitability, and market sentiment. High-growth companies command higher multiples, while mature, lower-growth companies trade at lower multiples. Compare Cronos Group to peers in the same sub-sector (MSO, LP, ancillary) for meaningful context.
Is CRON overvalued or undervalued based on P/S?+
A single metric like P/S cannot definitively determine if Cronos Group is over- or undervalued. Consider P/S alongside revenue growth rate, gross margins, cash position, and competitive dynamics. A company growing revenue at 50% YoY may justify a higher P/S than one growing at 5%. Also consider enterprise value-to-revenue (EV/Revenue) which accounts for debt and cash.